CRISPR Insider Kasinger Files Form 4 on Ownership Changes

TL;DR

**CRISPR insider Kasinger just filed a Form 4, watch for details on his stock moves.**

AI Summary

James R. Kasinger, a reporting insider for CRISPR Therapeutics AG, filed a Form 4 on March 24, 2026, indicating changes in his beneficial ownership of the company's securities as of March 20, 2026. While the filing details aren't fully provided in the snippet, a Form 4 typically reports transactions like stock sales, purchases, or option exercises. This matters to investors because insider transactions can signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.

Why It Matters

Insider transaction filings like this can provide clues about how company executives view the stock's value, which can influence investor sentiment and stock price.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing indicates a change in ownership, the specific details of the transaction (buy/sell, amount) are not provided in this snippet, making the immediate impact unclear.

Analyst Insight

A smart investor would seek out the full Form 4 document to understand the specific transactions made by James R. Kasinger, as this information could signal insider sentiment about CRISPR Therapeutics AG's future.

Key Players & Entities

• KASINGER JAMES R. (person) — Reporting insider for CRISPR Therapeutics AG
• CRISPR Therapeutics AG (company) — Issuer of the securities
• 0001708172 (person) — CIK for KASINGER JAMES R.
• 0001674416 (company) — CIK for CRISPR Therapeutics AG

Forward-Looking Statements

• The full Form 4 filing will reveal specific transaction details (e.g., buy/sell, quantity, price) by James R. Kasinger. (James R. Kasinger) — high confidence, target: 2026-03-24
• Depending on the nature of the transaction (e.g., a large sale), CRISPR Therapeutics AG's stock price might experience short-term volatility. (CRISPR Therapeutics AG) — medium confidence, target: 2026-03-25

FAQ

Filing Documents

• ownership.html (4)
• ownership.xml (4) — 12KB
• 0001193125-26-122274.txt ( ) — 14KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * KASINGER JAMES R. (Last) (First) (Middle) C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET (Street) BOSTON MASSACHUSETTS 02127 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) General Counsel and Secretary 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 03/20/2026 M (1) 6,250 A (2) 97,490 D Common Shares 03/23/2026 S 3,182 (3) D $ 46.78 94,308 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 46.24 03/20/2026 A (1) 38,499 (4) 03/20/2036 Common Shares 38,499 $ 0.00 38,499 D Restricted Stock Units (2) 03/20/2026 A (1) 25,000 (5) (5) Common Shares 25,000 $ 0.00 25,000 D Restricted Stock Units (2) 03/20/2026 M (1) 6,250 (6) (6) Common Shares 6,250 (2) 12,000 D Explanation of Responses: 1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. 3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. 4. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. 5. This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. 6. This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Elizabeth Ryland Waldinger, attorney-in-fact 03/24/2026 ** Signature of Reporting

View Full Filing

View this 4 filing on SEC EDGAR